News

The senior academic at the University of Sydney discussed the reasons for using BC-LCLA and the modified MS Functional Composite in the phase 2 VISIONARY-MS trial. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Teri Schreiner, MD, associate professor at the University of Colorado, talked about the impact of B-cell-depleting therapy in pediatric patients with MS infected with COVID-19.

At the 2023 AAN Annual Meeting, the chief medical officer at Athira Pharma spoke about findings from a phase 2 trial in which various biomarkers related to neurodegeneration showed significant improvements. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Jean-Cosme Dodart, PhD, senior vice president of research at Vaxxinity, discussed the progress of the UB-312 Parkinson disease vaccine, highlighting its findings from a phase 1 clinical trial, and plans for a phase 2 trial.

Positive associations between preexisting obstructive sleep apnea and probable post-acute sequelae among adults were attenuated but remained significant after adjusting for other comorbidities.

Neurology News Network for the week ending May 13, 2023. [WATCH TIME: 4 minutes]

The FDA is set to make a final decision later this month and, if approved, SRP-9001 would be the first gene therapy specific to treat Duchenne muscular dystrophy.

The senior academic at the University of Sydney provided perspective on the promising findings of the phase 2 VISIONARY-MS study of CNM-Au8 in relapsing multiple sclerosis. [WATCH TIME: 6 minutes]

Alternative multiple sleep latency test parameters was found to be a better identification method for recognizing hypocretin-deficiency among patients with hypersomnolence and narcolepsy.

The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation spoke about her talk on new treatments for drug resistant epilepsy given at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Taken together, the findings added to the growing evidence that widespread immunological and autonomic nervous system changes may contribute to long COVID.

Findings showed that pediatric patients with narcolepsy who have had at least 2 components of metabolic syndrome may be at higher risk of future complications.

The medical director of SleepMed in South Carolina provided perspective on the importance of understanding the link between sleep disorders, poor sleep, and heart health. [2 minutes]

The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

The approval was based on 2, positive phase 3 studies in which brexpiprazole-treated patients demonstrated a 31% greater reduction in frequency of agitation symptoms vs those on placebo.

The strongest associations observed in the study were between microglial activation at the rim of chronic T1 hyperintense lesion and in the perilesional normal appearing white matter and serum neurofilament light.

Findings showed that obstructive sleep apnea can cause early cognitive decline in middle-aged men even if they are healthy and nonobese.

The chief scientific officer at Alzheon provided insight on the preliminary imaging findings of patients enrolled in the phase 3 APOLLOE4 study assessing ALZ-801 as a potential treatment for Alzheimer disease. [WATCH TIME: 3 minutes]

Jeffrey Bennett, MD, PhD, professor of neurology and ophthalmology at the University of Colorado Denver talked about inebilizumab for patients with NMOSD from the N-MOmentum trial.

The chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]

To date, the enzyme replacement therapy had been studied in a comprehensive clinical development program that comprised more than 140 patients with Fabry disease with up to 7.5 years of follow up treatment.

The senior vice president of research at Vaxxinity talked about research for a potential vaccine for migraine prevention presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.

In transgenic mouse models, treatment with PMN310 resulted in preserved memory, to the extent that treated mice were indistinguishable from non-transgenic control mice.

Nicholas Johnson, MD, MSci, FAAN, division chief of neuromuscular disorders and vice chair of research, Virginia Commonwealth University, provided insight on promising phase 1/2 data of AOC 1001 in myotonic dystrophy type 1.

The associate professor of neurology at Mayo Clinic Rochester discussed specific findings from a simultaneous comparison of migraine medications in which certain treatments and classes were more effective. [WATCH TIME: 3 minutes]